Investigating treatments to counteract long-term nerve damage from chemical warfare agents
Saracatinib and 1400W Counteract Nerve Agents-Induced Long-Term Neurotoxicity
This study is looking at new ways to help people who have been exposed to harmful nerve agents, aiming to find better treatments that can protect the brain and improve recovery for those who have experienced long-term effects.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iowa State University NIH-funded |
| Lab location | 1 site (Ames, United States) |
| Project ID | NIH-10904888 on NIH RePORTER |
What this research studies
This research focuses on developing effective treatments for individuals exposed to chemical warfare nerve agents (CWNAs), which can cause severe long-term neurological damage. The study aims to evaluate the combined effects of two neuroprotectants, saracatinib and 1400W, alongside existing medical countermeasures to mitigate neurotoxicity and restore brain function. By using animal models that simulate the effects of CWNA exposure, the research seeks to understand how these treatments can prevent cognitive and motor impairments that often follow such exposure. Patients who have survived CWNA attacks may benefit from the findings of this research, as it aims to provide new therapeutic options for their long-term care.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to chemical warfare nerve agents and are experiencing long-term neurological effects.
Not a fit: Patients who have not been exposed to chemical warfare agents or those without neurological impairments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life for survivors of chemical warfare exposure by reducing long-term neurological damage.
How similar studies have performed: Previous research has shown promising results with similar neuroprotective approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Ames, United States
- Iowa State University — Ames, United States (Active)
Researchers
- Principal investigator: Thippeswamy, Thimmasettappa — Iowa State University
- Study coordinator: Thippeswamy, Thimmasettappa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.